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Abstract
Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF)
patients to an increased risk of stroke. This study describes the real-world discontinuation
rates and compared the risk of drug discontinuation among NVAF patients initiating apixa-
ban, warfarin, dabigatran, or rivaroxaban. This retrospective cohort study evaluated newly-
anticoagulated NVAF patients in the MarketScan® data population from 01/01/2012 through
12/31/2014. Discontinuation was defined as a lack of subsequent prescription of the index
drug within 30 days after the last supply day of the last prescription. A Cox model was used
to estimate the hazard ratio (HR) of discontinuation, adjusted for age, sex, and comorbidi-
ties. Among 45,361 eligible NVAF patients, 15,461 (34.1%) initiated warfarin; 7,438 (16.4%)
apixaban; 4,661 (10.3%) dabigatran; and 17,801 (39.2%) initiated rivaroxaban treatment.
Compared to warfarin, patients who initiated dabigatran (adjusted HR [aHR]: 0.84, 95% con-
fidence interval [CI]: 0.80–0.87, P<0.001), rivaroxaban (aHR: 0.70, 95% CI: 0.68–0.73,
P<0.001), or apixaban (aHR: 0.57, 95% CI: 0.55–0.60, P<0.001) were 16%, 30%, and 43%
less likely to discontinue treatment, respectively. When compared to apixaban, patients who
initiated dabigatran (aHR: 1.46, 95% CI: 1.38–1.54, P<0.001) or rivaroxaban (aHR: 1.23,
95% CI: 1.17–1.28, P<0.001) were more likely to discontinue treatment. Among newly-antic-
oagulated NVAF patients in the real-world setting, initiation on rivaroxaban, dabigatran, or
apixaban was associated with a significantly lower risk of discontinuation compared to war-
farin. When compared to apixaban, patients who initiated treatment with warfarin, dabiga-
tran, or rivaroxaban were more likely to discontinue treatment.
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Introduction
While warfarin is highly effective for preventing stroke in patients with atrial fibrillation (AF),
there is significant inter- and intra-patient variability in dose requirements, thus necessitating
regular anticoagulation monitoring. Warfarin is also associated with many diet and drug inter-
actions and can be associated with a significant rate of major bleeding, particularly intracranial
hemorrhage [1,2]. Given these difficulties, many at-risk AF patients do not receive warfarin or
receive an inadequate dose, and often discontinue therapy [1,2]. As a result, approximately
30–50% of patients have been undertreated with either suboptimal warfarin treatment, aspirin,
or no anticoagulation [3]. In recent years, 4 non-Vitamin K antagonist oral anticoagulants
(NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, have been approved in
the United States for stroke prevention in NVAF patients. The NOACs have advantages over
warfarin in that there is no need for regular International Normalized Ratio (INR) monitoring,
and there are fewer drug and food interactions. In clinical trials assessing warfarin, dabigatran,
rivaroxaban, apixaban, and edoxaban, all have been shown to be safe and effective [4–7].
Among all NOACs approved for non-valvular AF (NVAF), apixaban is the only drug that has
shown, in its respective clinical trial(s), to have a significantly lower discontinuation rate than
warfarin (or aspirin) possibly due to its significantly better safety and tolerability profile
[6,8,9]. Due to the moderate half-life of NOACs, it is important for patients to continue to take
medications daily, as indicated. For both warfarin and NOACs, drug discontinuation and
missing doses (ie, lower adherence) may expose AF patients to an increased risk of stroke.
Consequently, studies of discontinuation and adherence associated with NOACs are impor-
tant in understanding treatment patterns and associated gaps [10,11,12]. It would be important
to investigate discontinuation rates and time to discontinuation associated with various
NOACs to understand the ability of patients to continue long-term NOAC use in real-world
settings. The objective of this study was to describe the ‘real-world’ discontinuation rates and
compare the risk of drug discontinuation among patients initiating apixaban, dabigatran, riv-
aroxaban, and warfarin. For the purposes of this analysis, there were insufficient real-world
data available for edoxaban in the United States.
Methods
A retrospective cohort study was conducted using the Truven MarketScan1 Commercial
Claims & Encounters and Medicare Supplemental & Coordination of Benefits database (Janu-
ary 2012 through December 2014) to evaluate the discontinuation rates among AF patients
who initiated apixaban, warfarin, dabigatran, or rivaroxaban treatment [13]. The database
includes health insurance claims for over 60 million employees, spouses, retirees, and their
dependents, enrolled in employer-sponsored commercial and Medicare advantage plans. The
geographical distribution is approximately the same as the US population distribution. The
database includes fully-integrated health information, including inpatient and outpatient
health care resource utilization and detailed drug information. The pharmaceutical claims file
includes complete records of prescriptions, including mail-order or card program prescription
drug claims [13].
NVAF patients aged18 years (identified based on presence of at least 1 claim for a pri-
mary or secondary diagnosis of AF in the inpatient or outpatient setting using ICD-9-CM
code 427.31 or 472.32) with a 1-year baseline period with continuous health plan enrollment
were included if they were newly prescribed oral anticoagulants from January 1, 2013 through
December 31, 2014 [14]. The ICD-9 codes have been validated for identifying AF patients with
a median positive predictive value of 89% [14]. In other words, a contemporary cohort of
NOAC and warfarin initiators without prior oral anticoagulant treatment during the 1-year
Discontinuation risk: Warfarin and NOACs
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baseline period was selected for this study. The index drug was defined as the first anticoagula-
tion treatment prescribed to patients included in the study. The index date was defined as the
first index drug prescription date, after NVAF diagnosis. The index date is depicted in Fig 1.
Patients with claims including ICD-9-CM diagnosis codes for transient AF (pericarditis,
hyperthyroidism, thyrotoxicity), valvular heart disease, venous thromboembolism, cardiac sur-
gery, or pregnancy during the baseline period (any time prior to or on the index date) were
excluded (Fig 2; S1 Table).
Discontinuation was defined as a gap in therapy when a subsequent prescription for the
index treatment occurred>30 days, plus the days supply of the previous prescription [12].
Patients who did not discontinue treatment were followed until the date of a switch to another
anticoagulant, end of the study period, inpatient death, or interruption in continuous health
plan enrollment, whichever occurred earliest. A sensitivity analysis was completed by changing
the discontinuation gap to 60 days and 90 days.
A second sensitivity analysis was also performed. Due to varying mean length of follow-up
across treatment cohorts, only patients who had at least 100 days of follow-up were included,
in order to assess the robustness of the estimated risk of discontinuation.
In the study population, categorical and continuous variables were compared across treat-
ments using the Pearson chi-square test and the Wilcoxon rank-sum test, respectively. The
proportions of patients discontinuing therapy during the study follow-up period were com-
puted as the number of patients who discontinued treatment divided by the total number of
patients initiating the treatment within the study period. The cumulative incidence of discon-
tinuation was presented using Kaplan–Meier curves. A Cox proportional hazards model was
used to estimate the hazard ratios (HRs) of discontinuation for each drug compared to apixa-
ban, adjusted for a pre-specified set of baseline demographic and clinical factors including age,
sex, embolic or primary ischemic stroke, dyspepsia or stomach discomfort, congestive heart
Fig 1. Study period depiction. Study period for patients initiating apixaban, dabigatran, rivaroxaban, and warfarin. AF: atrial fibrillation.
https://doi.org/10.1371/journal.pone.0195950.g001
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failure, coronary artery disease, diabetes mellitus, hypertension, renal disease, myocardial
infarction, history of stroke, or transient ischemic attack, and history of bleeding (S1 Table).
As warfarin is the standard of care, we have analyzed and presented the primary results
using warfarin as a reference comparator. Lower discontinuation rates were observed for
NOACs in real-world studies and clinical trials; therefore, we also analyzed apixaban as a refer-
ence cohort to understand the discontinuation risk associated with NOACs and warfarin in
Fig 2. Patient selection criteria. Study population flow chart with inclusion and exclusion criteria used to select 45,361 patients. NOAC: non-vitamin
K antagonist oral anticoagulant; VTE: venous thromboembolism.
https://doi.org/10.1371/journal.pone.0195950.g002
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the real-word setting. All analyses were performed with SAS System version 9.2. An a priori
significance level of 0.05 was used for the purposes of these analyses.
Results
Among 45,361 patients, 15,461 (34.1%) initiated warfarin treatment with a mean (SD) follow-
up of 164 (±162) days; 7,438 (16.4%) initiated apixaban with a mean follow-up of 148 (±138)
days; 4,661 (10.3%) initiated dabigatran with a mean follow-up of 177 (±179) days; and 17,801
(39.2%) patients initiated rivaroxaban with a mean follow-up of 176 (±171) days (Table 1).
Approximately 60% of patients in each treatment group were male. The mean age of warfarin,
apixaban, dabigatran, and rivaroxaban patients was 71.7±12.0, 68.5±12.4, 66.5±12.4, and
Table 1. Baseline patient characteristics and treatment follow-up period.
Apixaban (n = 7,438) Dabigatran (n = 4,661) Rivaroxaban (n = 17,801) Warfarin (n = 15,461)
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Age 68.5 12.4 66.5 12.4 67.1 12.3 71.7 12.1
18–64 3111 41.8 2234 47.9 8245 46.3 4845 31.3
65–74 1805 24.23 1096 23.5 4208 23.6 3595 23.3
75+ 2522 33.9 1331 28.6 5348 30.0 7021 45.4
Sex
Male 4566 61.4 3028 65.0 11310 63.5 9254 59.9
Female 2872 38.6 1633 35.0 6491 36.5 6207 40.2
Embolic or Primary
Ischemic Stroke
523 7.0 259 5.6 1056 5.9 1551 10.0
Dyspepsia or Stomach Discomfort 1082 14.6 564 12.1 2548 14.3 2470 16.0
Congestive Heart Failure 1454 19.6 873 18.7 3293 18.5 4021 26.0
Coronary Artery Disease 2410 32.4 1283 27.5 5112 28.7 5305 34.3
Diabetes 2108 28.3 1269 27.2 4802 27.0 4987 32.3
Hypertension 5585 75.1 3253 69.8 12690 71.3 11334 73.3
Renal Disease 638 8.6 333 7.1 1398 7.9 2242 14.5
Myocardial Infarction 469 6.3 251 5.4 1089 6.1 1378 8.9
History of Stroke or TIA 754 10.1 413 8.9 1574 8.8 2061 13.3
History of Bleeding 1012 13.6 536 11.5 2421 13.6 2800 18.1
CHA2DS2-VASc Score
 2.8 1.6 2.6 1.7 2.6 1.7 3.2 1.7
0 514 6.9 485 10.4 1650 9.3 766 5.0
1 1222 16.4 908 19.5 3401 19.1 1809 11.7
2 1644 22.1 1027 22.0 3884 21.8 2750 17.8
3 4058 54.6 2241 48.1 8866 49.8 10136 65.6
Charlson Comorbidity Index Score 1.8 2.0 1.6 1.9 1.7 2.0 2.3 2.3
0 2244 30.2 1631 35.0 6117 34.4 3741 24.2
1 1899 25.5 1201 25.8 4468 25.1 3434 22.2
2 1270 17.1 729 15.6 2721 15.3 2499 16.2
3 2025 27.2 1100 23.6 4495 25.3 5787 37.4
Treatment Follow-up (in days) 148 138 177 178 175 171 164 162
Median 95 - 100 - 111 - 101 -
IQR 36–215 - 30–255 - 35–261 - 40–233 -
SD: Standard Deviation; TIA: Transient Ischemic Attack; IQR: Interquartile Range.
The CHA2DS2-VASc score was calculated as the sum of points associated with each of the following attributes: congestive heart failure (1 point), hypertension (1
point), age75 (2 points), diabetes (1 point), prior stroke or TIA (2 points), vascular disease (1 point), age 65–74 (1 point), female (1 point).
https://doi.org/10.1371/journal.pone.0195950.t001
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67.1±12.3 years, respectively. Patients initiating warfarin were older and were at higher risk in
terms of the CHA2DS2-VASc score (3.2±1.7) and had higher mean Charlson comorbidity
index (CCI) scores of 2.3±2.3 (Table 1).
Fig 3 shows the discontinuation rates of all drugs across the study period. The cumulative
incidence of discontinuation at one-year was 50.5%, 64.7%, 57.8%, and 71.6% for apixaban,
dabigatran, rivaroxaban, and warfarin patients, respectively. When the 60- and 90-day gap was
used, the rates of discontinuation were lower but the trend was consistent (S2 Table, S2 and S3
Figs). Across the four cohorts, around 3–10% of patients switched from index OAC to another
OAC during the follow-up period.
When compared to warfarin, patients who initiated dabigatran (adjusted HR [aHR]: 0.84,
95% confidence interval [CI]: 0.80–0.87), rivaroxaban (aHR: 0.70, 95% CI: 0.68–0.73,
P<0.001), or apixaban (aHR: 0.57, 95% CI: 0.55–0.60, P<0.001) were 16%, 30%, and 43% less
likely to discontinue treatment, respectively.
When compared to apixaban, patients who initiated warfarin (aHR: 1.74, 95% CI: 1.67–
1.82, P<0.001), dabigatran (aHR: 1.46, 95% CI: 1.38–1.54, P<0.001), and rivaroxaban (aHR:
1.23, 95% CI: 1.17–1.28, P<0.001) were significantly more likely to discontinue treatment,
after adjusting for baseline characteristics (Table 2 and Fig 3).
For sensitivity analysis, discontinuation was assessed among patients with at least 100 days
of follow-up, given the varied mean follow-up length across treatment cohorts in the main
Fig 3. Cumulative incidence of discontinuation among newly anticoagulated non-valvular atrial fibrillation patients. (Upper panel)
Cumulative incidence of discontinuation during the follow-up period. The unadjusted cumulative incidence of discontinuation was
lower among patients initiated on apixaban compared to patients inititated on other oral anticoagulants. (Lower panel) The number of
patients at risk for discontinuation at varying points during the follow-up.
https://doi.org/10.1371/journal.pone.0195950.g003
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analysis. This reduced the effective sample size to 13,294 patients (35.50%) initiating warfarin,
5,353 (14.29%) apixaban, 4,161 (11.11%) dabigatran, and 14,644 (39.10%) rivaroxaban.
When compared to warfarin, patients who initiated dabigatran (aHR: 0.89, 95% CI: 0.85–
0.92, P<0.001), rivaroxaban (aHR: 0.72, 95% CI: 0.70–0.74, P<0.001), or apixaban (aHR: 0.61,
95% CI: 0.58–0.64, P<0.001) were less likely to discontinue treatment (S3 and S4 Tables and
Fig 3). When compared to apixaban, patients who initiated warfarin (aHR: 1.64, 95% CI: 1.57–
1.71, P<0.001), dabigatran (aHR: 1.45, 95% CI: 1.37–1.53, P<0.001), or rivaroxaban (aHR:
1.18, 95% CI: 1.12–1.23, P<0.001) were more likely to discontinue treatment (S1 and S3
Tables; Fig 1).
Discussion
When compared to those who initiated warfarin, patients who initiated dabigatran, rivaroxa-
ban, or apixaban were less likely to discontinue treatment after adjusting for baseline charac-
teristics. Further, when compared to apixaban, patients who initiated treatment with warfarin,
dabigatran, or rivaroxaban were more likely to discontinue treatment.
This study used real-world claims data from the US population to provide critical insights
regarding the risk of discontinuation in an adult NVAF population who initiated anticoagulant
treatment with apixaban, warfarin, rivaroxaban, or dabigatran therapy. Importantly, these
‘real-world’ results are consistent with the clinical trial findings for the respective NOACs and
Table 2. Adjusted hazard ratios of discontinuation.
Hazard Ratio Hazard Ratio 95%
Confidence Limits
P-value Hazard Ratio Hazard Ratio 95%
Confidence Limits
P-value
Warfarin 1.74 1.67 1.82 <0.001 1.00 Reference
Dabigatran 1.46 1.38 1.54 <0.001 0.84 0.80 0.87 <0.001
Rivaroxaban 1.23 1.17 1.28 <0.001 0.70 0.68 0.73 <0.001
Apixaban 1.00 Reference 0.57 0.55 0.60 <0.001
Covariates Included in Both Models Have the Same Estimates as Shown Below
Hazard Ratio Hazard Ratio 95% Confidence
Limits
P-value
Age (75+ as a reference category)
18–64 1.34 1.30 1.38 <0.001
65–74 0.99 0.96 1.03 0.554
Male 1.02 0.99 1.05 0.226
Embolic or Primary Ischemic Stroke 0.96 0.88 1.05 0.394
Dyspepsia or Stomach Discomfort 1.10 1.06 1.14 <0.001
Congestive Heart Failure 0.96 0.93 0.99 0.007
Coronary Artery Disease 1.01 0.98 1.04 0.557
Diabetes 0.89 0.87 0.92 <0.001
Hypertension 0.89 0.86 0.91 <0.001
Renal Disease 1.04 0.99 1.08 0.116
Myocardial Infarction 1.05 0.99 1.11 0.093
History of Stroke or Transient Ischemic Attack 0.85 0.79 0.92 <0.001
History of Bleeding 1.12 1.08 1.16 <0.001
Adjusted hazard ratios were estimated from a Cox proportional hazards model with factors for age, sex, embolic or primary ischemic stroke, dyspepsia or stomach
discomfort, congestive heart failure, coronary artery disease, diabetes, hypertension, renal disease, myocardial infarction, history of stroke or transient ischemic attack,
and history of bleeding.
https://doi.org/10.1371/journal.pone.0195950.t002
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warfarin. In the ARISTOTLE trial, for example, fewer patients in the apixaban group (25.3%)
compared to the warfarin group (27.5%) discontinued the study drug before the end of the
study (p = 0.001) [6]. In the ROCKET-AF trial, the proportion of patients who permanently
stopped their assigned therapy before an end-point event and before the termination date was
23.7% in the rivaroxaban group and 22.2% in the warfarin group [5]. In the RE-LY trial, the
rates of discontinuation for 110 mg of dabigatran, 150 mg of dabigatran, and warfarin were
14.5%, 15.5%, and 10.2%, respectively, at 1 year and 20.7%, 21.2%, and 16.6%, respectively, at 2
years [4].
The robustness of these findings through sensitivity analysis was also assessed, which largely
concurred with our primary findings by demonstrating a lower risk of discontinuation with
NOAC initiation as compared to warfarin, and a higher risk of discontinuation with initiation
on other anticoagulants as compared to apixaban.
Our results also confirm findings from recent ‘real-world’ studies. A long-term study of the
different NOACs in clinical practice showed that discontinuation rates were lower for apixa-
ban (10%) compared to dabigatran (30%) and rivaroxaban (25%; p<0.001 for both) [15].
Another study of NVAF patients who initiated oral anticoagulants showed significantly higher
1-year persistence rates with apixaban (86%) and warfarin (85%) than with dabigatran (74%)
or rivaroxaban (77%) [16]. Furthermore, in a propensity score-matched analysis, patients who
initiated dabigatran (63%) had higher persistence rates at 1 year compared to patients who ini-
tiated warfarin (39%) [12].
Discontinuation of anticoagulation or poor adherence to thromboprophylaxis is not incon-
sequential. Indeed, previous studies have found that warfarin discontinuation is associated
with increased risk of ischemic stroke. For example, Ewen, et al. [17] found that patients with 1
or 2 or more warfarin interruptions (defined as prescription gaps over 45 days) had higher
stroke incidence than those without warfarin interruption (relative risk: 2.29; 95% CI: 1.29–
4.07). Deitelzweig, et al. also found that stroke risk was higher with warfarin discontinuation
than during continuous warfarin therapy (HR: 1.60; 95% CI: 1.35–1.90) [18]. Similarly, in a
study by Spivey et al., discontinuation versus persistent use of warfarin was associated with
increased risk of ischemic stroke (HR: 2.04; 95% CI: 1.47–2.84) and ischemic stroke or TIA
(HR: 1.50; 95% CI: 1.20–1.87) [19].
The anticoagulant effect of NOACs decreases rapidly; therefore, poor adherence and treat-
ment discontinuation may diminish the benefit of NOAC treatment [20]. A higher risk of
thromboembolism was noted at the end of the double-blind trials during the transition from
rivaroxaban to open-label warfarin [21]. A recent analysis from the ROCKET-AF trial showed
an increased risk of stroke and non-central nervous system embolism among rivaroxaban-
treated versus warfarin-treated AF patients who temporarily or permanently discontinued
anticoagulation (HR: 1.50, 95% CI: 1.05–2.15) [21]. Furthermore, a longitudinal outcomes
study using a national cohort from the Veterans Health Administration showed that lower
adherence to dabigatran was associated with an increased risk of combined all-cause mortality
and stroke (HR: 1.13, 95% CI: 1.07–1.19 per 10% decrease in proportion of days covered) [22].
However, several ‘real-world’ studies have demonstrated reduced or similar ischemic stroke
risk among patients treated with NOACs compared with warfarin, suggesting adequate adher-
ence to maintain the benefits of NOACs [20].
Our results are also consistent with indirect comparisons that combined data from the
RELY, ROCKET-AF, and ARISTOTLE studies in relation to the discontinuation of treatment
[23]. While the reasons for discontinuation, causality between any particular attribute, and dis-
continuation of therapy cannot be determined in this retrospective study, the safety and tolera-
bility profile of a drug likely plays a critical role in patients’ ability to use NOACs continuously.
For example, a 2012 study showed the rate of discontinuation of dabigatran was 25.4%, with
Discontinuation risk: Warfarin and NOACs
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dyspepsia being the most common reason for discontinuation [24]. Further, a single clinical
center cross-sectional study in the United States reported that the most common reasons for
discontinuation with dabigatran were adverse reactions and cost [25].
The study’s strengths are that we assessed the real-world risk of discontinuation of treat-
ment among patients initiating warfarin versus dabigatran, rivaroxaban, and apixaban using
the comprehensive MarketScan1 claims database, which incorporates all medical and phar-
macy patient claims and allows for longitudinal analysis of a nationally-representative sample.
The medications being studied are relatively new to the market, and this database, encompass-
ing both commercial and Medicare beneficiaries, allows for the selection of a nationally-repre-
sentative sample for this study [13].
As with any retrospective analysis, researchers are limited to only study associations
between variables; additionally, as with any retrospective observational database study, there is
a potential for selection bias. We conducted rigorous and thorough multivariate and sensitivity
analyses for discontinuation to ensure the robustness of our findings. Baseline comorbidities
(eg, presence of renal impairment) were determined by the presence of a diagnosis code in the
baseline period and were not based on actual laboratory test result values or clinical assess-
ment. As this study is an analysis of claims data, there is the potential for coding errors or
missing data (ie, we must assume that patients do not have a condition if it was not coded).
Additionally, refill data may not reflect actual medication use. Discontinuation rates of warfa-
rin, as assessed by a 30-day gap in pharmacy claims, may vary more due to dose adjustments
to manage fluctuation in INR values compared to NOACs. As apixaban had entered the mar-
ket recently when the analysis was performed, patients treated with apixaban tended to have a
shorter follow-up than those treated with warfarin.
Further analyses using propensity-matched cohorts as well as large-scale prospective studies
may be necessary to understand the reasons for and predictors of discontinuation, and to
examine the impact of discontinuation on clinical outcomes.
Conclusions
Among newly-anticoagulated AF patients in the real-world setting, treatment initiation with
rivaroxaban, dabigatran, or apixaban was associated with a significantly lower risk of discon-
tinuation as compared to warfarin. Treatment discontinuation risk was significantly higher
among patients initiating dabigatran, rivaroxaban, or warfarin, as compared to those initiating
apixaban.
Supporting information
S1 Fig. Cumulative incidence of discontinuation: With a 60-day gap.
(TIF)
S2 Fig. Cumulative incidence of discontinuation: With a 90-day gap.
(TIF)
S3 Fig. Cumulative incidence of discontinuation: Minimum 100 days follow-up.
(TIF)
S1 Table. ICD-9-CM codes for selection criteria and comorbid conditions.
(DOCX)
S2 Table. Cumulative incidence of discontinuation at 1 year.
(DOCX)
Discontinuation risk: Warfarin and NOACs
PLOS ONE | https://doi.org/10.1371/journal.pone.0195950 April 30, 2018 9 / 11
S3 Table. Patient characteristics: Minimum 100 days follow-up.
(DOCX)
S4 Table. Adjusted risk of discontinuation: Minimum 100 days follow-up.
(DOCX)
Acknowledgments
Hemant Phatak was an employee of BMS at the time of this research. The authors are grate-
ful to Todd Durham (Pre-doctoral Fellow, Worldwide Health Economics and Outcomes
Research, Bristol-Myers Squibb Company) for his editorial assistance in the preparation of
this manuscript.
Author Contributions
Conceptualization: Gregory Y. H. Lip, Shital Kamble, Jack Mardekian, Cristina Masseria,
Hemant Phatak.
Formal analysis: Xianying Pan, Hugh Kawabata.
Methodology: Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian.
Writing – original draft: Gregory Y. H. Lip, Shital Kamble, Hemant Phatak.
Writing – review & editing: Gregory Y. H. Lip, Xianying Pan, Shital Kamble, Hugh Kawabata,
Jack Mardekian, Cristina Masseria, Hemant Phatak.
References
1. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding
with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Arch Intern Med. 2010; 170(16):1433–41. https://doi.org/10.1001/archinternmed.2010.271 PMID:
20837828
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who
have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857–67. PMID: 17577005
3. Ogilvie IM, Newton N, Welner SA Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation:
a systematic review. Am J Med. 2010; 123(7):638–45. https://doi.org/10.1016/j.amjmed.2009.11.025
PMID: 20609686
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfa-
rin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–51. https://doi.org/10.1056/
NEJMoa0905561 PMID: 19717844
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883–91. https://doi.org/10.1056/
NEJMoa1009638 PMID: 21830957
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus war-
farin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–92. https://doi.org/10.1056/
NEJMoa1107039 PMID: 21870978
7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus war-
farin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093–104. https://doi.org/10.1056/
NEJMoa1310907 PMID: 24251359
8. Phatak HM, Thomas J 3rd. Relationships between beliefs about medications and nonadherence to pre-
scribed chronic medications. Ann Pharmacother. 2006; 40(10):1737–42. https://doi.org/10.1345/aph.
1H153 PMID: 16985088
9. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how
unintentional is it really? BMC Health Serv Res. 2012; 12:98. https://doi.org/10.1186/1472-6963-12-98
PMID: 22510235
Discontinuation risk: Warfarin and NOACs
PLOS ONE | https://doi.org/10.1371/journal.pone.0195950 April 30, 2018 10 / 11
10. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD et al. Apixaban for reduction in
stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Am Heart J. 2010; 159(3):331–9. https://doi.org/10.1016/j.ahj.2009.07.035 PMID: 20211292
11. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S. Apixaban in patients with atrial fibril-
lation. N Engl J Med. 2011; 364(9):806–17. https://doi.org/10.1056/NEJMoa1007432 PMID: 21309657
12. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y. Higher persistence in newly diagnosed nonvalv-
ular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes.
2013; 6(5):567–74. https://doi.org/10.1161/CIRCOUTCOMES.113.000192 PMID: 23922182
13. Adamson DM, Chang S, Hansen LG. Health research data for the real world: the MarketScan® data-
bases. Thomson Medstat Research and Pharmaceutical Division; 2008. http://depts.washington.edu/
chaseall/pdfs/white%20paper_Thomson%20Reuters%20WP%20MarketScan%20Databases%
200708.pdf. Accessed July 10, 2016
14. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. Identifying atrial fibrillation from
electronic medical data: a systematic review. Pharmacoepidemiol Drug Saf. 2012; 21(01):141–7.
15. Al-Khalili F, Lindstro¨m C. Discontinuation rates in patients with non-valvular atrial fibrillation treated with
non-vitamin K antagonist oral anticoagulants (NOACs) are mainly related to drug specific side effects
and bleeding. Poster presented at: European Society of Cardiology (ESC) Congress; August 29-Sep-
tember 2, 2015; London.
16. Forslund R, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral antico-
agulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016; 72(3):329–38. https://doi.org/10.
1007/s00228-015-1983-z PMID: 26613954
17. Ewen E, Zhang Z, Simon TA, Kolm P, Liu X, Weintraub WS. Patterns of warfarin use and subsequent
outcomes in atrial fibrillation in primary care practices. Vasc Health Risk Manag. 2012; 8:587–98.
https://doi.org/10.2147/VHRM.S34280 PMID: 23112579
18. Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, et al. Warfarin use and stroke
risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther.
2013; 35(8):1201–10. https://doi.org/10.1016/j.clinthera.2013.06.005 PMID: 23867114
19. Spivey C, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H, et al. Stroke associated with discontinua-
tion of warfarin therapy for atrial fibrillation. Curr Med Res Opin. 2015; 31(11):2021–9. https://doi.org/
10.1185/03007995.2015.1082995 PMID: 26390258
20. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart
Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients
with non-valvular atrial fibrillation. Europace. 2015; 17(10):1467–507. https://doi.org/10.1093/europace/
euv309 PMID: 26324838
21. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, et al. Outcomes of discontinu-
ing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the
ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K
antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2013;
61(6):651–8. https://doi.org/10.1016/j.jacc.2012.09.057 PMID: 23391196
22. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adherence to dabiga-
tran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration. Am
Heart J. 2014; 167(6):810–7. https://doi.org/10.1016/j.ahj.2014.03.023 PMID: 24890529
23. Mitchell SA, Simon TA, Raza S, Jakouloff D, Orme ME, Lockhart I, et al. The efficacy and safety of oral
anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and
meta-analysis. Clin Appl Thromb Hemost. 2013; 19(6):619–31. https://doi.org/10.1177/
1076029613486539 PMID: 23698729
24. Ho JC, Chang AM, Yan BP, Yu CM, Lam YY, Lee VW. Dabigatran compared with warfarin for stroke
prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol. 2012; 35(12):E40–5. https://doi.
org/10.1002/clc.22069 PMID: 23108916
25. Jacobs A, Linn D, Sipe B, Heyerly A, Bokhart G. Evaluation of reasons for dabigatran discontinuation in
a community hospital and anticoagulation clinic. Hosp Pharm. 2014; 49(2):115–6. https://doi.org/10.
1310/hpj4902-115 PMID: 24623863
Discontinuation risk: Warfarin and NOACs
PLOS ONE | https://doi.org/10.1371/journal.pone.0195950 April 30, 2018 11 / 11
